Management of Venous Thromboembolism in Morbid Obesity With Rivaroxaban or Warfarin.

Paige WeaverTsz Hin NgThomas BreedenStephanie B EdwinChristopher Alan Giulianonull nullChristopher Giuliano

Published in: The Annals of pharmacotherapy (2022)

No difference was observed in obese patients with weight >120 kg or BMI >40 kg/m<sup>2</sup> receiving rivaroxaban or warfarin for VTE treatment in hazard of VTE or major bleeding. Either agent may be considered an appropriate treatment option in this population.

Keyphrases

venous thromboembolism
direct oral anticoagulants
atrial fibrillation
weight loss
metabolic syndrome
body mass index
weight gain
type diabetes
adipose tissue
physical activity
combination therapy
obese patients
skeletal muscle